The Case for Compounding Pharmacy
Lane Powell Shareholder Ron Friedman authored a November 9 Law360 article titled “The Case for Compounding Pharmacy.” In the article, Friedman discussed the benefits of compounding pharmacies, as well as The Markey bill, which would eliminate many of these benefits.
There is an old adage in the law that bad facts can produce bad law, and the same is true for legislation. Whenever there is a public event that is tragic in nature, as is the meningitis outbreak linked to the New England Compounding Center (“NECC”) in Massachusetts, there comes the inevitable wringing of hands and the cry for additional legislation. Respectfully, the tragic events of NECC do not point up the need for additional legislation, such as that recently proposed by U.S. Representative Edward Markey, D-Mass., before Congress (titled “Verifying Authority and Legality in Drug Compounding Act of 2012”) (HR 6584). To the contrary, what these events markedly and sadly suggest is that the regulatory authorities were simply asleep at the proverbial wheel.